Lupin’s FY26 Momentum Rides On U.S. Growth

Lupin has reported a strong Q1 FY26 with over 50% profit growth and improved margins. Robust U.S. sales—driven by new launches and FDA approvals—along with steady India growth, have fuelled the performance. Continued investments in R&D, compliance, and digital innovation are anchoring Lupin’s long-term strategy.